Published in Eur J Clin Nutr on March 01, 2006
Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in the Islamic Republic of Iran. Bull World Health Organ (2009) 2.16
Assessment of Risk Factors in Patients With Myocardial Infarction. Glob J Health Sci (2015) 0.79
The long-term effect of screening and lifestyle counseling on changes in physical activity and diet: the Inter99 Study - a randomized controlled trial. Int J Behav Nutr Phys Act (2015) 0.76
Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet (1981) 7.05
The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med (1990) 2.85
The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication. Eur J Vasc Endovasc Surg (2006) 2.74
Coronary risk factors and socioeconomic status. The Oslo study. Lancet (1976) 2.67
Four-year mortality by some socioeconomic indicators: the Oslo study. J Epidemiol Community Health (1980) 2.48
Lung cancer and air pollution: a 27 year follow up of 16 209 Norwegian men. Thorax (2003) 2.43
The Oslo study. Cardiovascular disease in middle-aged and young Oslo men. Acta Med Scand Suppl (1975) 2.30
Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet (1992) 2.22
Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet (1980) 1.75
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) Thromb Haemost (1997) 1.73
Panic disorder in chest pain patients referred for cardiological outpatient investigation. J Intern Med (1999) 1.55
Adipose tissue pro-inflammatory gene expression is associated with cardiovascular disease. Int J Clin Pract (2011) 1.54
High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study. Br Med J (1978) 1.50
Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma. Arteriosclerosis (1990) 1.46
Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The Oslo study. Am J Med (1978) 1.42
A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med (2003) 1.39
[Alpha blockaders--first or second line antihypertensive agents?]. Tidsskr Nor Laegeforen (1993) 1.38
Oslo Study Diet and Antismoking Trial. Results after 102 months. Am J Med (1986) 1.35
Risk factors of stroke incidence and mortality. A 12-year follow-up of the Oslo Study. Stroke (1993) 1.31
Dietary intake of differently fed salmon; the influence on markers of human atherosclerosis. Eur J Clin Invest (2005) 1.30
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) (2010) 1.28
Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care (1997) 1.27
Streptokinase of heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study. Acta Med Scand (1982) 1.24
Physical activity at work and at leisure in relation to coronary risk factors and social class. A 4-year mortality follow-up. The Oslo study. Acta Med Scand (1981) 1.22
Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis (2004) 1.21
Coronary risk factors in various occupational groups: the Oslo study. Br J Prev Soc Med (1977) 1.16
Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol (1996) 1.15
A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand (1978) 1.14
Possible metabolic side effects of beta-adrenergic blocking drugs. Br Med J (1978) 1.14
Body mass index and patterns of mortality among Seventh-day Adventist men. Int J Obes (1991) 1.12
The Oslo Study: diet and antismoking advice. Additional results from a 5-year primary preventive trial in middle-aged men. Prev Med (1985) 1.12
Validity of selected physical activity questions in white Seventh-day Adventists and non-Adventists. Med Sci Sports Exerc (1996) 1.11
Self-report of physical activity and patterns of mortality in Seventh-Day Adventist men. J Clin Epidemiol (1991) 1.11
Treatment of mild hypertension with diuretics. The importance of ECG abnormalities in the Oslo Study and in MRFIT. JAMA (1984) 1.10
High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery (1979) 1.09
[Diagnosis and treatment of familial hypercholesterolemia in children and adolescents]. Tidsskr Nor Laegeforen (1995) 1.08
A randomized primary preventive trial in coronary heart disease: the Oslo study. Prev Med (1983) 1.08
Four and two-thirds years incidence of coronary heart disease in middle-aged men: the Oslo study. Am J Epidemiol (1980) 1.08
Mean HbA1c over 18 years predicts carotid intima media thickness in women with type 1 diabetes. Diabetologia (2005) 1.06
Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Eur Heart J (1998) 1.04
Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost (2000) 1.03
Smoking habits and risk of fatal stroke: 18 years follow up of the Oslo Study. J Epidemiol Community Health (1996) 1.03
Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul Fibrinolysis (1995) 0.99
Effect of long-term changes in diet and exercise on plasma leptin concentrations. Am J Clin Nutr (2001) 0.99
n-3 polyunsaturated fatty acids and cardiovascular diseases. Lipids (2001) 0.97
Effects of anthocyanins on cardiovascular risk factors and inflammation in pre-hypertensive men: a double-blind randomized placebo-controlled crossover study. J Hum Hypertens (2012) 0.97
The intercorrelation of serum cholesterol, cigarette smoking and body weight. The Oslo Study. Acta Med Scand (1976) 0.97
Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res (1995) 0.97
Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals. J Clin Microbiol (2001) 0.96
Combined administration of dextran 70 and dalteparin does not increase perioperative blood loss compared to dextran 70 alone in major orthopedic surgery. Haemostasis (1999) 0.95
One year's experience of medical intensive care units. Acta Med Scand (1970) 0.95
Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the Oslo Study. Stroke (1995) 0.95
LPS-induced release of IL-1 beta, IL-6, IL-8, TNF-alpha and sCD14 in whole blood and PBMC from persons with high or low levels of HDL-lipoprotein. Cytokine (1994) 0.94
The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol (1999) 0.93
Different binding of 125I-LPS to plasma proteins from persons with high or low HDL. Scand J Clin Lab Invest (1996) 0.92
Evaluation of running conditions for SSCP analysis: application of SSCP for detection of point mutations in the LDL receptor gene. PCR Methods Appl (1993) 0.92
Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res (1993) 0.92
A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand (1978) 0.91
Socio-economic status as a coronary risk factor: the Oslo study. Acta Med Scand Suppl (1982) 0.91
A controlled study of peroral glucose, insulin and potassium treatment in myocardial infarction. Acta Med Scand (1971) 0.91
Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost (2003) 0.91
Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris. Scand J Clin Lab Invest (2008) 0.90
Effect of smoking cessation on markers of inflammation and endothelial cell activation among individuals with high risk for cardiovascular disease. Scand J Clin Lab Invest (2007) 0.90
Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. Diabetologia (2006) 0.90
Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res (2000) 0.89
LPS induced release of IL-1 beta, IL-6, IL-8 and TNF-alpha in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL. Cytokine (1996) 0.89
Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia. Clin Biochem (2004) 0.88
Standardization of a flow cytometric method for measurement of low-density lipoprotein receptor activity on blood mononuclear cells. Cytometry (1995) 0.88
Coronary risk factors and their pathway of action through coronary raised lesions, coronary stenoses and coronary death. Multivariate statistical analysis of an autopsy series: the Oslo Study. Am J Cardiol (1985) 0.88
Effects of a low glycemic load diet versus a low-fat diet in subjects with and without the metabolic syndrome. Nutr Metab Cardiovasc Dis (2009) 0.88
Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur J Clin Invest (1998) 0.87
Prognostic significance of ECG-changes in survivors of myocardial infarction. Five-year follow-up study. Acta Med Scand (1970) 0.87
Risk factors and raised atherosclerotic lesions in coronary and cerebral arteries. Statistical analysis from the Oslo study. Arteriosclerosis (1981) 0.87
The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens (1996) 0.87
A novel form of factor VII in plasma from men at risk for cardiovascular disease. Br J Haematol (1985) 0.87
The effect of an increased intake of vegetables and fruit on weight loss, blood pressure and antioxidant defense in subjects with sleep related breathing disorders. Eur J Clin Nutr (2007) 0.87
Changes in serum levels of E-selectin correlate to improved glycaemic control and reduced obesity in subjects with the metabolic syndrome. Scand J Clin Lab Invest (2005) 0.87
2 -Macroglobulin, 1 -antitrypsin, and antithrombin III in plasma and serum during fibrinolytic therapy with urokinase. Scand J Clin Lab Invest (1972) 0.87
Diet and exercise intervention have favourable effects on blood pressure in mild hypertensives: the Oslo Diet and Exercise Study (ODES). Blood Press (1995) 0.87
Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia (2005) 0.87
Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res (2008) 0.86